betway必威登陆网址 (betway.com )学报››2023,Vol. 44››Issue (5): 392-395.DOI:10.3969/j.issn.2097-0005.2023.05.014
收稿日期:
2022-11-11出版日期:
2023-05-25发布日期:
2023-06-14通讯作者:
王韶轩作者简介:
岳娜,硕士研究生,研究方向:炎症性肠病-溃疡性结肠炎的发病机制,E-mail:979971939@qq.com。基金资助:
Received:
2022-11-11Online:
2023-05-25Published:
2023-06-14Contact:
Shaoxuan WANG摘要:
溃疡性结肠炎(ulcerative colitis,UC)是一种影响结肠、直肠的慢性特发性炎症性疾病,近年来随着UC发病率逐渐增高,有关UC治疗的研究越来越受到重视。胰高血糖素样肽?2(glucagon like peptide?2,GLP?2)是一种在营养摄入的反应中释放的胃肠激素。GLP?2与GLP?2受体(glucagon like peptide?2 receptor,GLP?2R)结合后具有促进营养吸收、降低炎症反应、改善肠道血流灌注、促进肠黏膜增殖,改善肠道屏障功能等作用。GLP?2对肠道的有益作用,为UC的治疗提供了新方法、新思路。
岳娜, 王韶轩. 胰高血糖素样肽‑2改善溃疡性结肠炎的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(5): 392-395.
Na YUE, Shaoxuan WANG. Research progress of glucagon like peptide-2 and ulcerative colitis[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(5): 392-395.
1 | Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases[J]. Gastroenterology, 2011, 140(6): 1785. |
2 | Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review[J]. Gastroenterology, 2012, 142(1): 46. |
3 | Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences[J]. Gastroenterology, 2004, 126(6): 1504. |
4 | Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study[J]. Gut, 2014, 63(3): 423. |
5 | Danese S, Fiocchi C. Ulcerative colitis[J]. N Engl J Med, 2011, 365(18): 1713. |
6 | Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis[J]. Lancet, 2017, 389(10080): 1756. |
7 | Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis[J]. Gastroenterol Clin North Am, 2020, 49(4): 643. |
8 | Moldoveanu AC, Diculescu M, Braticevici CF. Cytokines in inflammatory bowel disease[J]. Rom J Intern Med, 2015, 53(2): 118. |
9 | Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease[J]. Nature, 2012, 491(7422): 119. |
10 | Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations[J]. Nat Genet, 2015, 47(9): 979. |
11 | McGovern DP, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases[J]. Gastroenterology, 2015, 149(5): 1163. |
12 | Feuerstein JD, Moss AC, Farraye FA. Ulcerative colitis[J]. Mayo Clin Proc, 2019, 94(7): 1357. |
13 | 邴新帅, 桑丹, 孙海洲, 等. 胰高血糖素样肽-2的研究进展[J]. 家畜生态学报, 2019, 40(6): 7. |
14 | Drucker DJ. Glucagon-like peptides[J]. Diabetes, 1998, 47(2): 159. |
15 | 高艳红, 徐洪雨. 胰高血糖素样肽-2治疗溃疡性结肠炎机制的研究进展[J]. 国际消化病杂志, 2022, 42(5): 274. |
16 | Mutanen A, Pakarinen MP. Serum fasting GLP-1 and GLP-2 associate with intestinal adaptation in pediatric onset intestinal failure[J]. Clin Nutr, 2017, 36(5): 1349. |
17 | Besa EC, Chandwe K, Banda R, et al. Glucagon-like peptide 2 concentrations vary in Zambian children during diarrhoea, in malnutrition and seasonally[J]. J Pediatr Gastroenterol Nutr, 2020, 70(4): 513. |
18 | Cai J, Zhou L, Song X, et al. Alteration of intestinal microbiota in 3-deoxyglucosone-induced prediabetic rats[J]. Biomed Res Int, 2020, 2020: 8406846. |
19 | Hartmann B, Harr MB, Jeppesen PB, et al.In vivoandin vitrodegradation of glucagon-like peptide-2 in humans[J]. J Clin Endocrinol Metab, 2000, 85(8): 2884. |
20 | Feng Y, Demehri FR, Xiao W, et al. Interdependency of EGF and GLP-2 signaling in attenuating mucosal atrophy in a mouse model of parenteral nutrition[J]. Cell Mol Gastroenterol Hepatol, 2017, 3(3): 447. |
21 | Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions[J]. Science, 2012, 336(6086): 1262. |
22 | Wu J, Ren W, Li L, et al. Effect of aging and glucagon-like peptide 2 on intestinal microbiota in SD rats[J]. Aging Dis, 2018, 9(4): 566. |
23 | Hvistendahl MK, Naimi RM, Enevoldsen LH, et al. Effect of glepaglutide, a long-acting glucagon-like peptide-2 analog, on gastrointestinal transit time and motility in patients with short bowel syndrome: findings from a randomized trial[J]. JPEN J Parenter Enteral Nutr, 2020, 44(8): 1535. |
24 | Hansen LB. GLP-2 and mesenteric blood flow[J]. Dan Med J, 2013, 60(5): B4634. |
25 | Martchenko SE, Sweeney ME, Dimitriadou V, et al. Site-specific and temporal effects of apraglutide, a novel long-acting glucagon-like peptide-2 receptor agonist, on intestinal growth in mice[J]. J Pharmacol Exp Ther, 2020, 373(3): 347. |
26 | Akiba Y, Maruta K, Takajo T, et al. Lipopolysaccharides transport during fat absorption in rodent small intestine[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318(6): G1070. |
27 | Maruta K, Takajo T, Akiba Y, et al. GLP-2 acutely prevents endotoxin-related increased intestinal paracellular permeability in rats[J]. Dig Dis Sci, 2020, 65(9): 2605. |
28 | Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans[J]. Gastroenterology, 2006, 130(1): 44. |
29 | Eliasson J, Hvistendahl MK, Freund N, et al. Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: an open-label phase 1 and 2 metabolic balance trial[J]. JPEN J Parenter Enteral Nutr, 2022, 46(7): 1639. |
30 | 沈桂英, 张杰. 细胞因子在溃疡性结肠炎发病机制中的作用[J]. 中国煤炭工业医学杂志, 2009, 12(2): 334. |
31 | Sigalet DL, Wallace LE, Holst JJ, et al. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2[J]. Am J Physiol Gastrointest Liver Physiol, 2007, 293(1): G211. |
32 | Lee M, Rhee MK. Sitagliptin for type 2 diabetes: a 2015 update[J]. Expert Rev Cardiovasc Ther, 2015, 13(6): 597. |
33 | Ning MM, Yang WJ, Guan WB, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2[J]. Acta Pharmacol Sin, 2020, 41(11): 1446. |
34 | Li D, Yang Y, Yin X, et al. Glucagon-like peptide (GLP) -2 improved colonizing bacteria and reduced severity of ulcerative colitis by enhancing the diversity and abundance of intestinal mucosa[J]. Bioengineered, 2021, 12(1): 5195. |
[1] | 李文玉, 杨洪娜, 方巍, 宋璇, 王春亭.脓毒症相关性脑病的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(9): 707-711. |
[2] | 吕昂, 张焱, 李鸣.老年免疫病的研究现状[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(8): 636-640. |
[3] | 褚微, 张冰, 纪洪.HMGCS2在疾病中的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(7): 546-551. |
[4] | 汤京云, 卢美琪, 张婷, 祁琳.中药穴位贴敷治疗溃疡性结肠炎的Meta分析[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(7): 507-513. |
[5] | 蒋鲁杰, 王燕, 邓仰欣, 曹铭锋.微小RNA在早期糖尿病肾病中的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(6): 452-456. |
[6] | 杭宇昕, 于佳琦, 曹燕凤, 徐宁, 刘景林, 许良.基于网络药理学探讨蒙药翻白草治疗2型糖尿病的作用机制[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(3): 191-196. |
[7] | 赵明清, 宋林, 李袁婧, 杜怡峰.扩大的血管周围间隙发生机制及其与认知功能障碍的关系[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(1): 63-66. |
[8] | 白金霞, 张婷, 卢美琪, 卢贞.溃疡性结肠炎体外模型研究进展[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(8): 631-634. |
[9] | 赵秦英, 张梅.TGF‐β信号通路与结肠癌5‐FU耐药性的发生机制[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(6): 466-470. |
[10] | 张青青, 刘珊珊, 王英惠, 柳刚.达格列净治疗慢性肾脏病的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(5): 388-392. |
[11] | 韩明丽, 田丹, 车欣宇, 余金毅, 肖昂, 潘国军, 肖娜.基于网络药理学研究金银花对糖尿病的作用机制[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(3): 172-177. |
[12] | 廖杰, 杜以梅.术后心房颤动发病机制的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(12): 891-896. |
[13] | 赵敏, 秦树存.氢气生物医学效应的发现、研究与应用[J]. betway必威登陆网址 (betway.com )学报, 2021, 42(5): 339-346. |
[14] | 赵春晖, 李占斌, 辛静昕, 张新焕, 高聆.Prader-Willi综合征代谢表型与遗传研究进展[J]. betway必威登陆网址 (betway.com )学报, 2021, 42(12): 941-946. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||